Als Failed Approaches Autopsy represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
This page performs a systematic postmortem analysis of every major failed ALS clinical trial to extract actionable lessons for future research. For each failure, we assess five key dimensions: target validity, drug potency, CNS delivery, patient selection, and trial design. Understanding WHY trials fail is critical for identifying what WILL work.
Each failed approach is scored on five dimensions (0-10 each, max 50 points):
| Dimension | Question | 10 = Best |
|---|---|---|
| Target Validity | Was the biological target truly disease-relevant? | Genetic/functional evidence definitively links target to ALS |
| Drug Potency | Was the compound sufficiently powerful? | Nanomolar potency demonstrated in relevant models |
| CNS Delivery | Did the drug reach therapeutic levels in the CNS? | Proven CNS exposure in human PET/CSF studies |
| Patient Selection | Were the right patients enrolled? | Biomarker-enriched cohort with confirmed pathology |
| Trial Design | Were endpoints, duration, and power appropriate? | Phase 3-ready design with validated biomarkers |
Company: Biogen Idec
Mechanism: Sodium channel blocker, mitochondrial protector
Outcome: Failed in EMPOWER trial (n=943)
| Dimension | Score | Analysis |
|---|---|---|
| Target Validity | 6/10 | Sodium dysregulation is downstream, not causal |
| Drug Potency | 4/10 | Weak mitochondrial protection at achievable doses |
| CNS Delivery | 7/10 | Good brain penetration, but insufficient exposure |
| Patient Selection | 5/10 | No biomarker enrichment, heterogeneous population |
| Trial Design | 7/10 | Reasonable design but perhaps too ambitious |
| TOTAL | 29/50 |
Lesson: Downstream symptom targeting without disease modification is insufficient. The drug showed mitochondrial effects but not strongly enough to slow progression.
Company: Biogen Idec
Mechanism: Antibiotic with glutamate transporter enhancement
Outcome: Failed in CLARITY trial (n=513)
| Dimension | Score | Analysis |
|---|---|---|
| Target Validity | 5/10 | Glutamate excitotoxicity is upstream of many downstream effects |
| Drug Potency | 3/10 | Antibiotic not optimized for CNS glutamate transport |
| CNS Delivery | 5/10 | Poor CNS penetration despite high doses |
| Patient Selection | 5/10 | No glutamate transporter biomarker |
| Trial Design | 6/10 | Adequate but underpowered |
| TOTAL | 24/50 |
Lesson: Repurposed drugs often lack optimization. The antibiotic was never designed to modulate glutamate transporters at therapeutic levels.
Company: Pfizer/Protalix
Mechanism: Recombinant glucocerebrosidase for Gaucher-ALS hypothesis
Outcome: Failed in terminally ill patients
| Dimension | Score | Analysis |
|---|---|---|
| Target Validity | 4/10 | GBA mutations increase ALS risk but relationship is complex |
| Drug Potency | 6/10 | Enzyme replacement works for Gaucher, not ALS |
| CNS Delivery | 2/10 | Cannot cross blood-brain barrier |
| Patient Selection | 3/10 | Enrolled advanced patients |
| Trial Design | 5/10 | Short duration, unclear endpoints |
| TOTAL | 20/50 |
Lesson: Peripheral enzyme replacement cannot address CNS pathology. The GBA-ALS relationship may require gene therapy or small molecules that penetrate the CNS.
Company: Various
Outcome: Repeated failures
The original edaravone formulation (MCI-186) failed in a 2005 Phase 3 trial (n=207) but later succeeded with optimized formulation (MCI-186-16) in 2017. This is a partial success story.
| Dimension | Score | Analysis |
|---|---|---|
| Target Validity | 7/10 | Oxidative stress is clearly involved in ALS |
| Drug Potency | 7/10 | Adequate free radical scavenging |
| CNS Delivery | 8/10 | Good brain penetration |
| Patient Selection | 4/10 | Initial trial enrolled too broad population |
| Trial Design | 6/10 | Later trials improved design |
| TOTAL | 32/50 |
Lesson: The original failure was patient selection, not mechanism. Later trials enriched for faster-progressing patients and showed benefit.
Company: Neuraltus Pharmaceuticals
Mechanism: Macrophage migration inhibitory factor (MIF) inhibitor
Outcome: Failed in晋級 trial
| Dimension | Score | Analysis |
|---|---|---|
| Target Validity | 5/10 | Neuroinflammation is important but may be downstream |
| Drug Potency | 4/10 | Insufficient potency against MIF |
| CNS Delivery | 4/10 | Limited CNS penetration |
| Patient Selection | 6/10 | Some biomarker enrichment (CRP) |
| Trial Design | 5/10 | Phase 2 design limitations |
| TOTAL | 24/50 |
Multiple trials of NSAIDs have failed, suggesting that broad anti-inflammatory approaches are insufficient.
| Dimension | Score | Analysis |
|---|---|---|
| Target Validity | 4/10 | Neuroinflammation is secondary, not primary driver |
| Drug Potency | 5/10 | NSAIDs not designed for CNS inflammation |
| CNS Delivery | 5/10 | Variable CNS penetration |
| Patient Selection | 3/10 | No inflammatory biomarker stratification |
| Trial Design | 5/10 | Generally underpowered |
| TOTAL | 22/50 |
Multiple Mesenchymal Stem Cell (MSC) and Neural Stem Cell (NSC) trials have shown safety but limited efficacy.
| Dimension | Score | Analysis |
|---|---|---|
| Target Validity | 6/10 | Cell replacement and trophic support rationale |
| Drug Potency | 7/10 | Cells can provide multiple trophic factors |
| CNS Delivery | 4/10 | Intrathecal delivery challenges, limited engraftment |
| Patient Selection | 4/10 | Typically late-stage patients |
| Trial Design | 4/10 | Small numbers, short follow-up |
| TOTAL | 25/50 |
Lesson: Cell therapy faces delivery and survival challenges. The right cell type, delivery method, and patient population remain unclear.
Gene therapy approaches for ALS face unique challenges.
| Dimension | Score | Analysis |
|---|---|---|
| Target Validity | 8/10 | SOD1 and C9orf72 targets are well-validated genetically |
| Drug Potency | 8/10 | ASOs can potently knock down gene expression |
| CNS Delivery | 3/10 | AAV delivery to motor cortex remains challenging |
| Patient Selection | 7/10 | Genetic stratification (SOD1, C9orf72) helps |
| Trial Design | 6/10 | Novel design challenges |
| TOTAL | 32/50 |
Lesson: CNS delivery is the key bottleneck. Even with valid targets and potent drugs, getting enough therapeutic to the right CNS regions is extremely challenging.
Tofersen showed promising results in the VALOR trial but did not meet primary endpoint in overall population.
| Dimension | Score | Analysis |
|---|---|---|
| Target Validity | 10/10 | SOD1 mutations cause ALS with high penetrance |
| Drug Potency | 10/10 | Potent ASO achieves >90% knockdown |
| CNS Delivery | 7/10 | Intrathecal delivery works, but distribution limited |
| Patient Selection | 8/10 | Enriched for SOD1 carriers, but still late stage |
| Trial Design | 8/10 | Well-designed but maybe too late for most |
| TOTAL | 43/50 |
Lesson: Even with the best target, drug, and design, treating after symptom onset may be too late. Pre-symptomatic treatment may be necessary.
Riluzole is the only approved ALS drug in the US (with Edaravone). It provides modest benefit (~2-3 months survival extension).
| Dimension | Score | Analysis |
|---|---|---|
| Target Validity | 7/10 | Glutamate excitotoxicity is a real contributor |
| Drug Potency | 6/10 | Modest glutamate modulation |
| CNS Delivery | 9/10 | Good brain penetration |
| Patient Selection | 5/10 | Broad population, no enrichment |
| Trial Design | 8/10 | Well-designed pivotal trials |
| TOTAL | 35/50 |
CNS Delivery is the Biggest Bottleneck
Patient Selection Matters More Than We Thought
Downstream vs. Upstream Targeting
Repurposing Has Limits
Timing May Be Everything
Based on failure analysis, what approaches have the best chance?
| Approach | Why It Might Work | Key Gap to Solve |
|---|---|---|
| SOD1 ASO (Tofersen) | Best target, potent drug, genetic validation | Earlier treatment, better delivery |
| C9orf72 approaches | Strong genetic link, clear mechanism | Delivery, antisense design |
| TDP-43 modulators | Core pathology in >95% of ALS | Target identification, drug discovery |
| Combination therapy | Multiple mechanisms may be needed | Trial design, regulatory pathways |
| Gene editing (CRISPR) | Permanent correction | Delivery, safety |
The study of Als Failed Approaches Autopsy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 6 references |
| Replication | 33% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 31%